Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729103 · ClinicalTrials.gov registry record
Treatment Patterns in Metastatic Prostate Cancer
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 565
- Enrollment target
NCT02729103: Completed study, sponsored by Bayer.
NCT02729103 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 565 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02729103 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 565 participants
- Enrollment target
Study Summary
This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.
Primary Outcome
Possible Treatment Types: Sipuleucel-T, Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium-223, Anti-Androgens, All other chemotherapy(oral and injectables), Radiation therapy
Interventions
- DRUG Xofigo (Radium 223 dichloride,BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2017-01-19 |
What the finished NCT02729103 record still lists
NCT02729103 is an observational study that tracks outcomes without assigning an intervention. The registered 565 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xofigo (Radium 223 dichloride,BAY88-8223) is the first listed.
NCT02729103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02729103 about?
NCT02729103 is a clinical study titled "Treatment Patterns in Metastatic Prostate Cancer". This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary obje...
What is the current status of trial NCT02729103?
This trial is currently completed. The enrollment target is 565 participants. The study started on 2016-10-31. Estimated completion is 2017-01-19.
What interventions are being tested in trial NCT02729103?
The interventions under investigation include: Xofigo (Radium 223 dichloride,BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02729103?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI